Allegro Ophthalmics, LLC   Report issue

For profit Phase 2
Founded: San Juan Capistrano CA United States (2011)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2011
NCT01482871
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Allegro Ophthalmics, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 2)

Edema (Phase 2)

Geographic Atrophy (Phase 2)

Macular Degeneration (Phase 2)

Macular Edema (Phase 2)

Retinal Diseases (Phase 2)

Tissue Adhesions (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 8